|
||
| |||||||
Cytomyx Licenses Cancer Database To Astrazeneca30
March 2004 Cytomyx Holdings plc (AIM: CYX), the leading provider of drug
discovery products and services, today announces that Clinomics Biosciences Inc,
its recently acquired US subsidiary, has licensed its Oncology Cell Signalling
Database to AstraZeneca, marking an important milestone for the Company. Clinomics’
Oncology Cell Signalling Database is based on a unique set of more than 30,000
human oncology samples, representing virtually all forms of cancer. The database
was created from Clinomics’ broad collection of more than 200,000 highly
characterised human samples, which form the basis for new genomic tools to
assist the pharmaceutical industry in the discovery of new drugs. Mike
Kerins, Cytomyx’ chief executive, said: “We are delighted that AstraZeneca
has chosen our Oncology Cell Signalling Database to assist in its cancer drug
discovery and the agreement marks a highly significant step following the
Clinomics acquisition “Clinomics’
technology enables us to offer critical new tools to pharmaceutical companies to
allow the biological characterisation of gene and protein targets across many
disease areas.” Under
the terms of the AstraZeneca purchase agreement, AstraZeneca has received
multiple user licences to the Oncology Cell Signalling Database along with
rights to database upgrades. Financial details of the agreement, which is
non-exclusive, are not being disclosed. Patrick
Muraca Ph.D., Clinomics Biosciences’ CSO, said: “We have analysed the
protein expression patterns of 100 cell signalling proteins across all of the
30,000 oncology samples and integrated this information into a new searchable
database. Researchers are able to interrogate a wide range of data fields within
the database including patient demographics, medical history, pathology and
treatment outcomes to identify factors important in disease progression.” Clinomics
was acquired by Cytomyx in December last year. For
more information: Karen
Chandler-Smith About
Cytomyx Holdings plc
Cytomyx
Holdings plc (www.cytomyx-holdings.com)
is a rapidly growing life science company based in Cambridge, UK. Its four
operating subsidiaries -Cytomyx Ltd, Clinomics Biosciences Inc, Cambridge
Bioscience Ltd and Cytocell Technologies Ltd – develop and market a wide range
of products and services to the pharmaceutical, diagnostics and academic
research markets. Cytomyx is listed on the London Stock Exchange’s Alternative
Investment Market in 2001. About
Clinomics Biosciences Inc
Clinomic
Biosciences Inc (www.clinomicsbio.com),a
wholly owned subsidiary of Cytomyx, offers database products for the biological
characterisation of gene and protein targets for use in drug discovery research.
The company has a collection of more than 200,000 highly characterised human and
biology samples and its proprietary Tissue MicroArray technology allows hundreds
of individual tissue samples to be arrayed on microscope slides for use in gene
and protein characterisation studies. About
AstraZeneca
AstraZeneca
is a major international healthcare business engaged in the research,
development, manufacture and marketing of prescription pharmaceuticals and the
supply of healthcare services. It is one of the top five pharmaceutical
companies in the world with healthcare sales of over $18.8 billion and leading
positions in sales of gastrointestinal, oncology, cardiovascular, neuroscience
and respiratory products. AstraZeneca is listed in the Dow Jones Sustainability
Index (Global and European) as well as the FTSE4Good Index. |
|
| ||||||||